Results 261 to 270 of about 7,176,843 (353)

Healthcare Professionals’ Preferences and Perceived Barriers for Routine Assessment of Patient‐Reported Outcomes in Pediatric Oncology Practice: Moving Toward International Processes of Change

, 2016
Sasja A. Schepers, Lotte Haverman, Sima Zadeh, Martha A. Grootenhuis, Lori Wiener   +4 more
openalex   +2 more sources

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

Molecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs   +11 more
wiley   +1 more source

Comprehensive Conservative Care for Kidney Failure - the Need for Evidence-Based Guidance

Kidney International Reports
Olalekan Lee Aiyegbusi
doaj   +1 more source

Evaluating the Feasibility of Electronic Patient-Reported Outcomes for a Population Receiving Specific Health Checkups: A Pilot Study. [PDF]

Healthcare (Basel)
Yano H, Hosogaya N, Ide S, Kawasaki R, Tadami T, Ide M, Murotani K.   +6 more
europepmc   +1 more source

Three-dimensional Preoperative Planning and Three-dimensional Printed Patient-Specific Instrument (PSI) for Total Hip Arthroplasty-Early Clinical Outcomes and Reports

Meng-Hsueh Tsai, Jen-Ting Huang, Cheng‐Ting Shih, Yi-Wen Chen, Jiann‐Jong Liau, Kui-Chou Huang   +5 more
openalex   +1 more source

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Health-Related Quality of Life in the Era of Immune Checkpoint Blockade: What Do Patient-Reported Outcomes Reveal? [PDF]

Cancers (Basel)
Dunker AM, Malik N, Krause KJ, Keung EZ, Liu JB, Nassif Haddad EF, Somaiah N, Lyu HG, Roland CL.   +8 more
europepmc   +1 more source

Electronic Patient-reported Outcomes in Cancer

Maryam Jafarpour
openalex   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source